{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "10697399",
  "DateCompleted": {
    "Year": "2000",
    "Month": "03",
    "Day": "21"
  },
  "DateRevised": {
    "Year": "2017",
    "Month": "03",
    "Day": "06"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "pol"
    ],
    "ELocationID": [],
    "Journal": {
      "JournalIssue": {
        "Volume": "101",
        "Issue": "3",
        "PubDate": {
          "Year": "1999",
          "Month": "Mar"
        }
      },
      "Title": "Polskie Archiwum Medycyny Wewnetrznej",
      "ISOAbbreviation": "Pol Arch Med Wewn"
    },
    "ArticleTitle": "[The usefulness of MIBI scintigraphy for postoperative monitoring of patients with thyroid cancer].",
    "Pagination": {
      "StartPage": "227",
      "EndPage": "232",
      "MedlinePgn": "227-32"
    },
    "Abstract": {
      "AbstractText": [
        "Metoxyizobutyloizonitrile labelled with technetium 99mTc is a radio-pharmaceutical that was shown to accumulate in benign and cancerous thyroid tissue. As it can be applied without thyroid hormone withdrawal this gave a stimulus to the investigations on its usefulness in diagnostic and follow up procedures for thyroid cancer patients. The goal of this study is to evaluate the efficacy and benefit of 99mTc-MIBI whole body scintigrams in post surgery follow-up of patients with differentiated thyroid cancer. One hundred and twenty eight 99mTc MIBI scintigraphy were performed and evaluated. Sensitivity of MIBI scans was the highest for bone metastases--79%. Good results were also obtained for lymph node metastases (sensitivity--73%, specificity--90%). In case of lung metastases the sensitivity and specificity were 21% and 94% respectively. Sensitivity of detection of clinically apparent recurrent disease in thyroid bed was 70% and specificity of visualization 78%. Results of our study demonstrate that 99mTC-MIBI is valuable tool in follow up of thyroid cancer patients, but can not replace 131I scintygraphy."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Zak\u0142ad Medycyny Nuklearnej i Endokrynologii Onkologicznej, Centrum Onkologii, Instytut im. M. Sk\u0142odowskiej-Curie, Oddzia\u0142 w Gliwicach."
          }
        ],
        "LastName": "Puch",
        "ForeName": "Z",
        "Initials": "Z"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Handkiewicz-Junak",
        "ForeName": "D",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Zajusz",
        "ForeName": "A",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Orlef",
        "ForeName": "A",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Roskosz",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Jarzab",
        "ForeName": "B",
        "Initials": "B"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Journal Article"
    ],
    "VernacularTitle": "Przydatno\u015b\u0107 scyntygrafii MIBI w monitorowaniu pooperacyjnym chorych na zr\u00f3znicowanego raka tarczycy."
  },
  "MedlineJournalInfo": {
    "Country": "Poland",
    "MedlineTA": "Pol Arch Med Wewn",
    "NlmUniqueID": "0401225"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "971Z4W1S09",
      "NameOfSubstance": "Technetium Tc 99m Sestamibi"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "diagnostic imaging",
        "secondary"
      ],
      "DescriptorName": "Bone Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Follow-Up Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "diagnostic imaging",
        "secondary"
      ],
      "DescriptorName": "Lung Neoplasms"
    },
    {
      "QualifierName": [
        "diagnostic imaging"
      ],
      "DescriptorName": "Lymphatic Metastasis"
    },
    {
      "QualifierName": [
        "diagnostic imaging"
      ],
      "DescriptorName": "Neoplasm Recurrence, Local"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Postoperative Period"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Radionuclide Imaging"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Sensitivity and Specificity"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Technetium Tc 99m Sestamibi"
    },
    {
      "QualifierName": [
        "diagnostic imaging",
        "secondary"
      ],
      "DescriptorName": "Thoracic Neoplasms"
    },
    {
      "QualifierName": [
        "diagnostic imaging",
        "surgery"
      ],
      "DescriptorName": "Thyroid Neoplasms"
    }
  ]
}